Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection
Qi Li(Qingdao University), Haopeng Sun(China Pharmaceutical University), Weixuan Lu(China Pharmaceutical University), Qinghong Liao(China Pharmaceutical University), Yuanyuan Wang(Peking University), Ying Chen(Xiamen University), Yao Chen(Central South University), Feng Feng(China Pharmaceutical University), Wenyuan Liu(China Pharmaceutical University), Shuaishuai Xing(China Pharmaceutical University), Siyu He(ShenZhen People’s Hospital), Baichen Xiong(China Pharmaceutical University)
Cited by 72
Related Papers
Degradation of proteins by PROTACs and other strategies
|Acta Pharmaceutica Sinica B|2019|312
Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease
|European Journal of Medicinal Chemistry|2017|307
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms
|Journal of Medicinal Chemistry|2019|270
Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease
|European Journal of Medicinal Chemistry|2018|200
Strategies for Structural Modification of Small Molecules to Improve Blood–Brain Barrier Penetration: A Recent Perspective
|Journal of Medicinal Chemistry|2021|196